Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione.

Brechbuhl HM, Kachadourian R, Min E, Chan D, Day BJ.

Toxicol Appl Pharmacol. 2012 Jan 1;258(1):1-9. doi: 10.1016/j.taap.2011.08.004. Epub 2011 Aug 10.

2.

Intracellular glutathione level and efflux in human melanoma and cervical cancer cells differing in doxorubicin resistance.

Drozd E, Gruber B, Marczewska J, Drozd J, Anuszewska E.

Postepy Hig Med Dosw (Online). 2016 Apr 18;70:319-28.

3.

Collateral sensitivity of resistant MRP1-overexpressing cells to flavonoids and derivatives through GSH efflux.

Lorendeau D, Dury L, Genoux-Bastide E, Lecerf-Schmidt F, Simões-Pires C, Carrupt PA, Terreux R, Magnard S, Di Pietro A, Boumendjel A, Baubichon-Cortay H.

Biochem Pharmacol. 2014 Aug 1;90(3):235-45. doi: 10.1016/j.bcp.2014.05.017. Epub 2014 May 27.

PMID:
24875445
4.

The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.

Majumder S, Dutta P, Mookerjee A, Choudhuri SK.

Chem Biol Interact. 2006 Feb 1;159(2):90-103. Epub 2005 Nov 10.

PMID:
16289015
5.

Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells.

Hatcher EL, Alexander JM, Kang YJ.

Biochem Pharmacol. 1997 Mar 7;53(5):747-54.

PMID:
9113095
6.

Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.

Zeng X, Morgenstern R, Nyström AM.

Biomaterials. 2014 Jan;35(4):1227-39. doi: 10.1016/j.biomaterials.2013.10.042. Epub 2013 Nov 7.

8.

Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis.

Mantawy EM, El-Bakly WM, Esmat A, Badr AM, El-Demerdash E.

Eur J Pharmacol. 2014 Apr 5;728:107-18. doi: 10.1016/j.ejphar.2014.01.065. Epub 2014 Feb 6.

PMID:
24509133
9.

Mechanism of resistance to oxidative stress in doxorubicin resistant cells.

Furusawa S, Kimura E, Kisara S, Nakano S, Murata R, Tanaka Y, Sakaguchi S, Takayanagi M, Takayanagi Y, Sasaki K.

Biol Pharm Bull. 2001 May;24(5):474-9.

10.

Modulation of doxorubicin cytotoxicity by ethacrynic acid.

Awasthi S, Singhal SS, He N, Chaubey M, Zimniak P, Srivastava SK, Singh SV, Awasthi YC.

Int J Cancer. 1996 Nov 4;68(3):333-9.

11.

Flavonoid-induced glutathione depletion: potential implications for cancer treatment.

Kachadourian R, Day BJ.

Free Radic Biol Med. 2006 Jul 1;41(1):65-76. Epub 2006 Mar 31.

12.

Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R).

Pesić M, Andjelković T, Banković J, Marković ID, Rakić L, Ruzdijić S.

Invest New Drugs. 2009 Apr;27(2):99-110. doi: 10.1007/s10637-008-9140-5. Epub 2008 May 21.

PMID:
18493718
13.

Hyperthermia improves therapeutic efficacy of doxorubicin carried by mesoporous silica nanocontainers in human lung cancer cells.

Lee H, Kim S, Choi BH, Park MT, Lee J, Jeong SY, Choi EK, Lim BU, Kim C, Park HJ.

Int J Hyperthermia. 2011;27(7):698-707. doi: 10.3109/02656736.2011.608217.

PMID:
21992562
14.

Role of caspases, Bax and Bcl-2 in chrysin-induced apoptosis in the A549 human lung adenocarcinoma epithelial cells.

Samarghandian S, Nezhad MA, Mohammadi G.

Anticancer Agents Med Chem. 2014;14(6):901-9.

PMID:
24521149
15.

[Effect of decreased GSH on sensitivity of breast cancer cells to ADM].

Han XQ, Li ZH, Zhang JG, Jiang YD, Peng KJ, Wang LZ, Wang SR.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Sep;38(5):770-4. Chinese.

PMID:
17953354
16.

Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.

Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.

Oncol Res. 1995;7(3-4):191-200.

PMID:
8555653
17.

Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.

Nestal de Moraes G, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP, Maia RC.

Eur J Cell Biol. 2013 Aug-Sep;92(8-9):247-56. doi: 10.1016/j.ejcb.2013.08.001. Epub 2013 Aug 31.

PMID:
24064045
18.

Changes in the activity of antioxidant barrier after treatment of K562 and CCRF-CEM cell lines with doxorubicin-transferrin conjugate.

Szwed M, Kania KD, Jozwiak Z.

Biochimie. 2014 Dec;107 Pt B:358-66. doi: 10.1016/j.biochi.2014.10.005. Epub 2014 Oct 13.

PMID:
25312849
20.

Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells.

Asakura T, Takahashi N, Takada K, Inoue T, Ohkawa K.

Anticancer Drugs. 1997 Feb;8(2):199-203.

PMID:
9073316

Supplemental Content

Support Center